CompletedPhase 1NCT00030498

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Antonius Miller
Cancer and Leukemia Group B
Intervention
erlotinib hydrochloride(drug)
Enrollment
75 enrolled
Eligibility
18 years · All sexes
Timeline
2001

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00030498 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials